- PROFESSOR EMERITUS Ophthalmology
Tel: (212) 241-5319
Fax: (212) 241-5945
Tel: (212) 241-7229
Fax: (212) 534-4498
Dr. Mittag has taught in team-teaching courses in Pharmacology and Neuroscience (medical student and graduate student levels). He has served as Program Director and Principal Investigator of a NIGMS Pharmacology Training Program grant for pre-doctoral trainees in Pharmacology. He has developed and teaches a 3-4 hour short course on Ocular Pharmacology given each year at MSSM and also teaches this course by invitation at other institutions such as Columbia University, University of Puerto Rico School of Medicine and the Manhattan Eye and Ear Infirmary. He has served as mentor and supervised the doctoral thesis research of four Ph.D. students, the training of fifteen post-doctoral fellows and of five Ophthalmology fellows.
\tAs a senior faculty member, Dr. Mittag has served on numerous ad hoc committees within the School of Medicine and the Graduate School of Basic Medical Sciences, such as on chairperson-search committees, patent application review committee, thesis examination committees, disciplinary committees and various teaching committees (graduate and medical). He has also served on institutional standing committees, including the Medical School Admissions Committee, The Tenure and Promotions Committee, and the Institutional Animal Care and Use Committee (IACUC).
\tSince 1976, Dr. Mittag has served on various committees of the major societies concerned with experimental eye research in the U.S. and internationally (ARVO, ICER), such as meeting or symposium organizer or section (subspecialty) chairperson. Additionally, he has or presently serves on the editorial boards of the major basic eye research journals. He is a reviewer for experimental eye research journals and pharmacology journals.
\tDr. Mittag's grant review activities include fellowship and grant-in-aid applications to private funding organizations and several NIH ad hoc review committees (NRSA fellowships, funding for buildings and major equipment, site-visits, special grant reviews, etc.). From 1989 to 1993, Dr. Mittag served on the Visual Sciences A Study Section, Division of Research Grants of the NIH.
Alcon Research Institute Award
Senior Investigator Award, Research to Prevent Blindness
Dr. Mittag's interests are in ocular pharmacology as it relates to drug mechanisms for aqueous humor dynamics in the primate eye, and glaucomatous retinopathy as it relates to stress signals and intracellular signal systems associated with survival, regeneration and death of retinal ganglion cells (RGC). An additional interest is light stress-induced intracellular signal systems involved in mediating the death of photoreceptors.\r\n
\r\n\tDr. Mittag and associates are currently working on the development and optimization of methods to assess glaucoma in rodent models including new non-invasive methods to determine IOP, retinal electrophysiology, imaging of the optic nerve head, and determination of peri-papillary blood flow. In addition, automated methods to quantitate surviving RGC and the pattern of RGC loss in rodent glaucoma models are being developed.\r\n
\r\n\tDr. Mittag's research studies involve collaborations with Drs. SM Podos, R-F Wang, W.G. Tatton, J.Danias and S.E. Brodie, all of the Mount Sinai School of Medicine.\r\n
Mittag TW, Danias J, Pohorenec G, Yuan HM, Burakgazi E, Chalmers-Redman R, Podos SM, Tatton WG. Retinal damage after 3-4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000; 41: 3451-3459.
Bayer AU, Neuhardt T, Brodie S, Martus P, Maag KP, Lutjen-Drecoll E, Mittag TW. Age-related changes in retinal morphology and ERG responses in the DBA/2 Nnia mouse model of angle closure glaucoma. Invest Ophthalmol Vis Sci 2001; 42: 1258-1265.
Kontiola AI, Goldblum D, Mittag T, Danias J. A new instrument to measure intraocular pressure in the rat. Exp Eye Res 2001; 73: 781-785.
Bayer AU, Danias J, Brodie S, Maag KP, Chen B, Shen F, Podos SM, Mittag TW. Electroretinographic abnormalities in a rat glaucoma model with chronic elevated intraocular pressure. Exp Eye Res 2001; 72: 667-677.
Tatton WG, Chalmers-Redman RM E, Sud A, Podos SM, Mittag TW. Maintaining Mitochondrial Membrane Impermeability: An Opportunity For New Therapy In Glaucoma?. Surv Ophthalmol 2001; 45: S277-S283.
Danias J, Shen F, Goldblum D, Chen B, Ramos-Esteban J, Podos SM, Mittag TW. Cytoarchitecture of the retinal ganglion cells in the rat retina. Invest Ophthalmol Vis Sci 2002; 43: 587-594.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Mittag is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.